RxDoctor Payments Data

Trikannad Prashanthkumar, MD

Endocrinology, Diabetes & Metabolism · Sidney, OHNPI 1023067428

Payments from drug & device makers

$597in general payments, 2019–2025

Across 38 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$144
  • Tandem Diabetes Care, Inc.$71
  • AstraZeneca$64
  • Insulet Corporation$55
  • Novo Nordisk$47
  • Xeris Pharmaceuticals, Inc.$42
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$597 in reported general payments places this provider in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$98,336
Medicare patients
401
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin306$263,719
MounjaroTirzepatide151$187,822
OzempicSemaglutide133$165,177
TrulicityDulaglutide108$138,266
Humulin R U-500 KwikpenInsulin Regular, Human67$130,325
FarxigaDapagliflozin Propanediol85$79,965
Lantus SolostarInsulin Glargine,hum.Rec.Anlog411$74,999
Tresiba Flextouch U-100Insulin Degludec89$66,774
Humalog Kwikpen U-100Insulin Lispro128$50,809
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog85$43,481
Fiasp FlextouchInsulin Aspart (Niacinamide)59$42,417
Novolog FlexpenInsulin Aspart144$38,111
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/724$38,106
ProliaDenosumab20$34,564
Humalog Kwikpen U-200Insulin Lispro16$34,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$144$339,863328 claims
Novo NordiskOzempic, Rybelsus, Novolog$47$196,025180 claims
AstraZenecaFarxiga$64$79,96585 claims
AmgenProlia$11$34,56420 claims
Sanofi-aventis U.S. LLCLantus$37$10,20632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Sidney

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →